NOVIL 76 EC

Principle Routes of Exposure

May be fatal if swallowed, inhaled, or absorbed through eye or skin. May produce acute cholinesterase depression. May cause corrosive destruction of the skin, mucous membranes produce acute cholinesterase depression May cause corrosive destruction of the skin. Mucous membranes and the eyes. Sings of acute overexposure Acute cholinesterase depression may be evidenced by headache, nausea, vomiting, deadhead, abdominal cramps, excessive sweating, salivation and tearing, constricted pupils, blurred vision, tightness in chest, weakness, muscle twitching and confusion; in extreme cases, unconsciousness, convulsions, severe respiratory depression and death may occur. This product is expected to be corrosive to the eyes. The degree of injury will depend on the amount and duration of the contact and the speed and thoroughness of the first aid treatment. Expected adverse health effects resulting from direct exposure to the eye may include pain, tears, swelling, redness, blurred vision, irreversible eye damage and possibly blindness. This product is expected to be corrosive to the skin. The degree of injury will depend on the amount and duration oldie contact and the speed and thoroughness of the first aid treatment. The expected adverse health effects resulting from a direct exposure to the skin may include pain or a feeling of heat, discoloration, swelling, blistering, and irreversible tissue damage. This product is expected to be corrosive to the digestive tract, and, if ingested, may cause nausea, vomiting and diarrhea. This product is expected to be corrosive to the respiratory tract, and, if inhaled, may cause symptoms that include nasal discharge, sore throat, coughing, bronchitis, pulmonary edema, and difficulty in breathing. Sings of Chronic overexposure Repeated exposures Cu small doses of Nalco and other organophosphates may lower the cholinesterase to levels where the above symptoms of acute overexposure are observed. Arclonogenicity There is no evidence of carcinogenicity in laboratory animals tested with Noted Technical. CARE SHOULD BE EXERCISED IN BANTLING THIS FORMULATION.MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: Preexisting conditions which lower cholinesterase levels increase vulnerability to cholinesterase depression. These include: (for plasma) genetic cholinesterase deficiency; advanced liver disease; chronic alcoholism; malnutrition; dermaunnyositis; existing toxicity from exposure to carbon disulfide; benzalkonium salts, organic mercury compounds, ciguatoxins or solacing; and hemolytic anemia’s.